BIOTRON LIMITED
(ASX:BIT)

Australia-China Biotech Invest

March 2017

Forward Looking Statements

This presentation may contain forward-looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they relate to Biotron Limited, are intended to identify forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Biotron’s current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ materially from current expectations.

Biotron Limited - Investment Highlights

- Spun out of the Australian National University (ANU), Canberra
- Based in Sydney, Australia
- Infectious disease focus
  - Broad platform with new class of anti-viral drugs
- Phase 2 clinical programs for multi-billion dollar markets
  - Hepatitis C virus (HCV)
  - HIV-1 eradication
- Pipeline of earlier stage anti-viral programs targeting broad range of viruses including respiratory viruses, Dengue virus, Hepatitis B virus and others
- Several near term, value-adding milestones anticipated for 2017

Developing New Class of Antiviral Drugs



Nature Reviews Microbiology **10**, 563-574

Viroporin proteins are present in influenza (M2), Hep C (p7), Dengue (M protein), SARS (E protein), HIV-1 (Vpu), and others

- Rapid bacterial screening assays set up for target proteins
- Developed specialised library of compounds to target VIROPORIN viral targets
- Pipeline of internally-generated, first-in-class small molecule viroporin inhibitors for key markets
- Focused on clinical development of lead drug BIT225 (HCV and HIV-1)
- Progressing promising earlier stage drug discovery programs for other viruses

Biotron

Core Technology Drives Rich Compound Library

Specialised, enriched antiviral library of over 350 compounds

“HITS” IN LIBRARY include:

- Influenza A and B
- Hepatitis B virus (HBV)
- Coronaviruses (Including SARS)
- Epstein-Barr virus (EBV)
- Zika virus
- Dengue virus
- Hepatitis C virus (HCV)
- HIV-1
- others

Library of compounds target viral proteins called Viroporins



BIT225 – PHASE 2 CLINICAL ASSET

- Identified by screening Biotron's compound library
- First in class drug and new drug target for treatment of Hepatitis C virus (HCV)
- Eight clinical trials completed
  - Over 200 subjects dosed in trials to date
- Promising clinical efficacy against HCV
  - HCV GT1 (BIT225-005) – 100% receiving 400mg BID for 28 days in combination with 48 weeks IFN/RBV (per protocol) were virus-free at 48 weeks
  - HIV-1/HCV GT3 (BIT225-006) – 100% receiving 300mg BID for 28 days in combination with 48 weeks IFN/RBV (per protocol) achieved SVR12 i.e. cured of HCV infection
  - BIT225 increases the rate at which HCV is cleared

BIT225 – NEW CLASS OF HEPATITIS C DRUG

- ✓ Novel, oral, small molecule compound
- ✓ Only one of its class (p7 inhibitor) in clinical trials
- ✓ Inhibits viral assembly and infectivity
- ✓ Pan-genotype activity:
  - ✓ Active *in vitro* against all main genotypes
  - ✓ Clinically active against hard-to-treat HCV GT 1 (1a and 1b) and GT 3



BIT225 – SEEKING PARTNERSHIPS IN ASIA REGION

- Seeking partnerships for further development of BIT225, in particular in Asia
- Emerging evidence that Interferon sparing therapies may cause reactivation of Hepatitis B (HBV)
  - Evidence of reactivation of hepatitis B in co-infected patients (HBV & HCV) presented at AASLD
  - 30 – 50 million HCV-infected subjects in China
    - High HCV/HBV co-infection rate in China
- Potential for another class of DAA such as BIT225 to shorten treatment and reduce costs

Unlocking Value in Compound Library

- Renewed industry interest in targeting viral diseases including
  - Respiratory diseases e.g. Respiratory syncytial virus (RSV) & Influenza
  - Hepatitis B virus
  - Tropical diseases including Dengue
- **BIT225 has demonstrated the robustness of Biotron's approach with targeting viroporin proteins**
- **Seeking partnerships for development programs targeting respiratory infections (including Influenza), Dengue, Hepatitis B virus and others, in addition to the clinical phase BIT225 HCV program**

Dr Michelle Miller
Managing Director
+61 412 313329
mmiller@biotron.com.au

www.biotron.com.au